A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | December 20, 2011 | ||||
Last Updated Date | June 8, 2012 | ||||
Start Date ICMJE | May 2012 | ||||
Estimated Primary Completion Date | July 2013 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Number of oocytes retrieved per subject following ovarian stimulation. [ Time Frame: At a time of 36 hours after r-hCG administration ] [ Designated as safety issue: No ] 36 (+/-2) hours after r-hCG administration |
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | Complete list of historical versions of study NCT01497197 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique | ||||
Official Title ICMJE | A Phase IIIb, Interventional, Multicentre, Multinational, Randomised, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 vs. Day 6 in Women Between 36 and 42 Years of Age Undergoing Assisted Reproductive Technique (ART) | ||||
Brief Summary | This is a phase IIIb, interventional, multicentre, multinational, randomised, open-label, comparative trial which primary objective is to generate data on the ovarian stimulation profile obtained when Luveris® is started either on day 1 or day 6 in women in advanced reproductive age (36-42) undergoing Assisted Reproductive Technique (ART). |
||||
Detailed Description | The subjects who have completed the screening assessments and fulfil all of the eligibility criteria will start down-regulation treatment on day 21-22 of the cycle. Down-regulation treatment must start within 2 months following the screening visit. The routine long luteal phase protocol for Gonadotrophin-releasing hormone (GnRH) agonist treatment will be followed. Once down-regulation has been confirmed, a pregnancy test will be performed within one week prior to start of Recombinant human follicle stimulating hormone (r-hFSH) treatment to rule out any pre-existing pregnancy. If the result is negative, the subject will be randomly assigned to one of the two treatment arms of the trial:
Randomisation across the two treatment arms will be kept balanced in a 1:1 ratio. Subjects will be provided with a subject diary and safety information to record daily dosing information for GONAL-f® and Luveris®. The diary card will also capture information about r-hCG and Crinone® administration and safety. Follicular development will be monitored according to the centre's standard practice by Ultrasound Scan (US) and/or Oestradiol (E2) levels, until the protocol r-hCG requirement is met (i.e., at least 1 follicle greater or equal to 18 mm and 2 follicles greater or equal to 16 mm). After this, a single injection of 250 mcg of r-hCG (Ovidrel®/Ovitrelle®), will be administered in order to induce final oocyte maturation. At a time of 34-38 hours after r-hCG administration, oocytes will be recovered vaginally under US monitoring. Oocytes will then be fertilized in vitro and embryos replaced 2-3 days after oocyte recovery. Ovum pick up (OPU), in vitro fertilisation (IVF), Embryo Transfer (ET) and luteal support will be performed as per centre's standard practice. In addition, Crinone 8%® (progesterone gel) will be administered once daily. A post-treatment safety visit will be performed for all subjects who received r-hCG (pregnant and non-pregnant) on post r-hCG Day 15-20. For subjects who have withdrawn from treatment (i.e. after starting Luveris® or GONAL f® but before r-hCG is given) this visit will take place 20-30 days after their first Luveris® or GONAL-f® treatment injection (excluding pregnancy testing). |
||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 3 | ||||
Study Design ICMJE | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Supportive Care |
||||
Condition ICMJE |
|
||||
Intervention ICMJE |
|
||||
Study Arm (s) |
|
||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Recruiting | ||||
Estimated Enrollment ICMJE | 208 | ||||
Estimated Completion Date | August 2013 | ||||
Estimated Primary Completion Date | July 2013 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Female | ||||
Ages | 36 Years to 42 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE |
|
||||
Location Countries ICMJE | United Arab Emirates | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT01497197 | ||||
Other Study ID Numbers ICMJE | EMR200061-506 | ||||
Has Data Monitoring Committee | No | ||||
Responsible Party | Merck KGaA | ||||
Study Sponsor ICMJE | Merck KGaA | ||||
Collaborators ICMJE | Merck Serono Middle East FZ LLC | ||||
Investigators ICMJE |
|
||||
Information Provided By | Merck KGaA | ||||
Verification Date | June 2012 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |